Navigation Links
Molecular basis for neurodegeneration in Ataxia telangiectasia
Date:4/14/2008

An upcoming paper from Dr. David Wassarman (University of Wisconsin School of Medicine and Public Health) in the May 1 issue of G&D lends new insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia.

Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ systems and is characterized by neurodegeneration and cancer predisposition. A-T is caused by recessive mutations in the ataxia telangiectasia mutated (ATM) gene.

While existing animal models have established how ATM mutations contribute to genomic instability and cancer susceptibility, Dr. Wassarmans paper reveals how ATM mutations cause neurodegeneration.

The scientists generated a Drosophila model of A-T, in which neurodeneneration occurs in the absence of induced DNA damage as it does in human A-T patients. Thus, Dr. Wassarmans model most faithfully recapitulates neurodegeneration associated with the human disease.

Using this model, Dr. Wassarman and colleagues determined ATM functions normally to prevent neurons from re-entering the cell cycle.

At the end of the day, ATM-dependent arrest of cell growth is critical for both neuron function and tumor suppression, explains Dr. Wassarman. Furthermore, he is excited by the findings, as they point to possible therapeutic potential of CDC25 and other cell cycle inhibitors to treat A-T as well as other neurodegenerative disorders.


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related biology news :

1. ESF conference probes waters mysterious interactions at molecular level
2. Power of molecular imaging reveals secrets of the heart
3. Computer simulations point to key molecular basis of cystic fibrosis
4. New edition of a classic molecular biology textbook from CSHL Press and Benjamin Cummings
5. Molecular Biology of the Cell celebrates 25 years of publication
6. Shilatifard Lab sheds light on molecular machinery required for translation of histone crosstalk
7. How molecular muscles help cells divide
8. Leading cause of death in preemies might be controlled by resetting a molecular switch
9. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
10. NIH selects LIAI for major study on allergy molecular causes and possible treatments
11. Potential new therapeutic molecular target to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
Breaking Biology Technology: